Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMA1-DiCo + Alhydrogel
- Development stage
- Unknown
- Lead developer
- European Vaccine Initiative
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AMA1-DiCo + Alhydrogel is a malaria vaccine candidate combining three recombinant variants of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1-DiCo) with Alhydrogel adjuvant. The AMA1-DiCo component is designed to provide broader protection against parasites with varying AMA1 sequences. Alhydrogel is an aluminum hydroxide gel adjuvant that enhances immune responses by improving antigen uptake by antigen-presenting cells and inducing a Th2 immune response.
- Other names
- PfAMA1-DiCo + Alhydrogel
02
Targets
AMA1 (Apical membrane antigen 1)
Beyond the preview
Go deeper on AMA1-DiCo + Alhydrogel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMA1-DiCo + Alhydrogel.